白云山：子公司药物克感利咽口服液进入III期临床试验

Core Viewpoint - The announcement indicates that Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has officially launched the Phase III clinical trial for the drug Kegang Liyan Oral Liquid, aimed at treating acute pharyngitis [1] Group 1: Product Details - Kegang Liyan Oral Liquid is classified as a Class 2.3 new drug, with a specification of 10 mL per bottle, designed to dispel wind, clear heat, and detoxify [1] - The projected sales revenue for Kegang Liyan Oral Liquid in 2024 is estimated at RMB 18.2852 million [1] Group 2: Financial Investment - As of September 2025, the project has incurred research and development expenses of approximately RMB 18.1542 million (unaudited) [1]